Last reviewed · How we verify

NCT05210712

Respiratory Rate Validation Study - RS001.2 Respiree Cardio-Respiratory Monitor

Completed Last updated 2 May 2022
What this trial tests

trial testing RS001.2 Respiree Cardio-Respiratory Monitor in A Minimum of 30 Adults, Ages 18 Years and Older in 30 participants. Completed in 10 February 2022.

Timeline
24 January 2022
Primary endpoint
10 February 2022
10 February 2022

Quick facts

Lead sponsorRespiree Pte Ltd
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date24 January 2022
Primary completion10 February 2022
Estimated completion10 February 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Respiree Pte Ltd

Who can join

18 and older, any sex, with A Minimum of 30 Adults, Ages 18 Years and Older. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the RS001.2 Respiree Cardio-Respiratory Monitor to the Reference, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Respiree Pte Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing